Primary hyperoxaluria type 2 (PH2) is a rare inherited disorder characterized by a disorder of oxalate metabolism, leading to excessive formation of this substance in the body. PH2 is caused by a deficiency of the enzyme hypoxialate dehydrogenase, which is involved in the metabolism of glycinate and its conversion to glycine. Increased oxalate levels can lead to the formation of calcium oxalate crystals in the kidneys, which can ultimately cause kidney damage and renal failure. This condition can predispose to cardiovascular and osteopathic complications, and also has a significant impact on the quality of life of patients.
History of the disease and interesting historical facts
Primary hyperoxaluria was first described in the medical literature in the mid-20th century, but its genetic and biochemical basis remained unclear. The first successful attempts to link the disease to specific genes were made in the 1990s, when it was established that PH2 is caused by mutations in the GRHPR gene, located on chromosome 2. Among the interesting historical facts, it can be noted that in the early 2000s, it became possible to develop molecular diagnostic methods that significantly improved the detection of the disease and its hereditary nature. Thanks to this, it became obvious that early diagnosis and effective treatment can significantly improve the quality of life of patients with this disease.
Epidemiology
The incidence of primary hyperoxaluria type 2 varies by population and location, according to various studies, but the generally accepted estimate is approximately 1 in 100,000 live births. In some ethnic groups, such as Amerindians and Iberians, the incidence may be higher. PH2 is more common in children and adults, although accurate statistics on the incidence remain limited due to the rarity of the disease and lack of awareness in the medical community.
Genetic predisposition to this disease
Primary hyperoxaluria type 2 is caused by mutations in the GRHPR gene, which codes for the enzyme glycine hypoxialate dehydrogenase. These mutations result in a deficiency of the enzyme and, as a result, increased oxalate formation in the body. Research shows that more than 30 different mutations have been identified in this gene, which may explain the wide range of clinical manifestations and severity of the disease. Examples of such mutations include nucleotide substitutions that result in the formation of an incorrect protein or its absence. Genetic testing can help confirm the diagnosis and identify carriers.
Risk factors for the development of this disease
Although primary hyperoxaluria type 2 is mostly hereditary, certain factors may contribute to its onset or severity of symptoms. These factors may include:
- Heredity: Having a family history of the disease increases the risk of it occurring in offspring.
- Age: PG2 can manifest at any stage of life, but the first symptoms often appear in childhood.
- Diet: Deficiencies of certain vitamins and minerals and eating foods high in oxalate may worsen the condition.
- Kidney disease: The presence of other kidney diseases can worsen the manifestations of PG2 and its consequences.
Diagnosis of this disease
Diagnosis of primary hyperoxaluria type 2 involves several steps, including:
- Main symptoms: often manifest as kidney stones, bleeding, abdominal and kidney pain.
- Laboratory tests: urine analysis for oxalate, creatinine and other metabolites.
- Radiological examinations: ultrasound of the kidneys and bladder, CT to detect stones.
- Other types of diagnostics: molecular genetic testing to confirm the diagnosis.
- Differential diagnosis: exclusion of other causes of hyperoxaluria, such as systemic or secondary hyperoxaluria.
Treatment
Treatment of primary hyperoxaluria type 2 should be individualized and multifaceted. The main approaches include:
- General treatment: symptom management, maintaining adequate hydration, following a low oxalate diet.
- Pharmacological treatment: drugs that help reduce oxalate levels in the body, including pyridoxine.
- Surgical treatment: In severe cases where renal complications are observed, nephrectomy or other interventions may be indicated.
- Other treatments: Alternative and integrative approaches such as herbal medicine may be used, but should be discussed with your doctor.
List of medications used to treat this disease
The most commonly used drugs among patients with primary hyperoxaluria type 2 include:
- Pyridoxine (vitamin B6): to reduce oxalate levels.
- Potassium Citrate: Helps prevent stone formation.
- Antioxidants and other supportive medications are sometimes used.
Disease monitoring
Monitoring of treatment and patient status in primary hyperoxaluria type 2 plays an important role in preventing complications. Key aspects of monitoring include:
- Regular urine tests for oxalate and other metabolites.
- Periodic ultrasound examinations and screenings to assess kidney function and the presence of stones.
- Assessment of clinical symptoms for timely detection of exacerbations and the need for treatment adjustments.
- Prognosis: With adequate treatment, most patients can lead a virtually normal life, although chronic kidney failure remains a possible complication.
Age-related features of the disease
Primary hyperoxaluria type 2 can present at any age, but the characteristics of the disease may vary depending on the age group. In children, symptoms often appear early in life, with the condition being detectable as early as adolescence. In adults, PH2 may progress more slowly, but the risk of complications such as chronic renal failure remains high.
Questions and Answers
- What is the cause of primary hyperoxaluria type 2? Type 2 GERD is caused by mutations in the GRHPR gene, which results in a deficiency of the enzyme hypoxialate dehydrogenase, causing oxalate to accumulate in the body.
- What are the main symptoms of this disease? The main symptoms include kidney stones, lower back and abdominal pain, and the possibility of blood in the urine.
- How is primary hyperoxaluria type 2 diagnosed? Diagnosis includes laboratory tests of urine, ultrasound examination of the kidneys and molecular genetic testing.
- What does treatment for this disease include? Treatment typically involves symptom management, a low-oxalate diet, and the use of pharmacologic agents to reduce oxalate levels.
- What is the prognosis for patients with primary hyperoxaluria type 2? With adequate treatment, many patients can lead normal lives, but the risk of kidney complications remains high.
